Anti-2,4-dinitrophenyl antibody (Anti-DNP)

Anti-2,4-dinitrophenyl (Anti-DNP) antibody is a specialized immunoglobulin that specifically recognizes the synthetic dinitrophenyl hapten, a chemical group not naturally found in the human body. Historically, these antibodies have been fundamental in immunology for studying the principles of hapten-carrier effects, antibody affinity maturation, and the mechanisms of Type I hypersensitivity (Eisen et al., 1952). In contemporary drug development, anti-DNP antibodies are utilized as the core component of modular, 'switchable' chimeric antigen receptor (CAR) T-cell systems, such as the UniCAR platform (Arndt et al., 2014). In this system, T-cells are engineered to express an anti-DNP CAR that is functionally 'off' until a DNP-conjugated adapter molecule is introduced to bridge the T-cell to a specific tumor antigen. This modularity allows for precise control over T-cell activity and the ability to target multiple antigens, addressing common challenges in immunotherapy such as on-target/off-tumor toxicity and antigen escape (Cartellieri et al., 2016). Furthermore, anti-DNP antibodies are clinically relevant in autoimmunity, as they are frequently detected in patients with systemic lupus erythematosus (SLE) due to cross-reactivity with deoxyribonucleoprotein complexes (Fish et al., 1981).

Other names

Anti-dinitrophenyl antibodyAnti-DNP immunoglobulinAnti-DNP IgGAnti-DNP IgEAnti-2,4-DNP

In modular immunotherapy platforms like UniCAR, the anti-DNP antibody (typically formatted as a single-chain variable fragment or scFv) serves as a universal receptor on T-cells. This receptor remains inactive until it binds to a bispecific adapter molecule—a 'target module'—that contains a DNP moiety and a tumor-specific binding domain. This binding event bridges the T-cell to the cancer cell, triggering T-cell activation, cytokine release, and tumor cell lysis (Cartellieri et al., 2016; Mitwasi et al., 2020).